GSK plc (LON:GSK)
| Market Cap | 71.22B |
| Revenue (ttm) | 32.17B |
| Net Income (ttm) | 5.49B |
| Shares Out | 4.02B |
| EPS (ttm) | 1.33 |
| PE Ratio | 13.34 |
| Forward PE | 9.91 |
| Dividend | 0.61 (3.41%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 4,732,544 |
| Average Volume | 8,909,610 |
| Open | 1,778.00 |
| Previous Close | 1,772.50 |
| Day's Range | 1,755.00 - 1,783.00 |
| 52-Week Range | 1,242.50 - 1,830.00 |
| Beta | 0.23 |
| RSI | 58.03 |
| Earnings Date | Oct 29, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
GSK (GSK): CDC Updates Vaccination and Autism Information
GSK (GSK): CDC Updates Vaccination and Autism Information
GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript
GSK Completes Acquisition of BREXAFEMME NDA for U.S. Market Relaunch
GSK Completes Acquisition of BREXAFEMME NDA for U.S. Market Relaunch
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
UK officials ‘working night and day to resolve NHS drug pricing row’
Patrick Vallance says government trying to rebuild relations with pharma industry as he outlines life sciences ambition The UK science minister has said officials are “working day and night” trying to...
The Best Healthcare Stock to Hold in Uncertain Times
Looking for a cheap, safe healthcare stock to buy? Take two shares of GSK and call me in the morning.
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
GSK CEO among candidates considered for Diageo leadership: FT
Diageo (DEO) has weighed multiple candidates including outgoing GSK (GSK) CEO Emma Walmsley for its leadership role as CEO search frustrates investors. Read more here.
GSK (GSK) Highlights Liver Disease Research Developments at AASLD 2025
GSK (GSK) Highlights Liver Disease Research Developments at AASLD 2025
GSK Pharma shares fall over 2% as Q2 revenue fell 3.1% YoY to Rs 980 crore
GSK Pharma shares slipped over 2% in early trade on Friday after the company announced its second-quarter (Q2) results for...
FDA Recognizes GSK's Dostarlimab for Rectal Cancer in Latest Voucher Pilot
FDA Recognizes GSK's Dostarlimab for Rectal Cancer in Latest Voucher Pilot
GlaxoSmithKline India reports higher second-quarter profit on specialty medicine growth
India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio.
GSK PLC (GSK) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance
GSK PLC (GSK) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance
Q3 2025 GSK plc Earnings Call Transcript
Q3 2025 GSK plc Earnings Call Transcript
3 Dividend Stocks for November 2025
This month's trio includes two ADRs.
We need clarity on big pharma’s tax breaks | Letters
Pharmaceutical giants like GSK should be more transparent about the generous tax breaks they get from the UK government, says Mike Lewis The outgoing chief executive of the pharmaceutical company GSK ...
Top global stories this week: GSK, Samsung and HSBC among notable names
GSK Shares Surge 4.9% on Strong Q3 Earnings and Raised 2025 Outlook
GSK Shares Surge 4.9% on Strong Q3 Earnings and Raised 2025 Outlook
GSK plc (GSK) Q3 2025 Earnings Call Transcript
GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare...
GSK (GSK) Surges on Strong Q3 Results and Improved Outlook
GSK (GSK) Surges on Strong Q3 Results and Improved Outlook
GSK boss: Britain must reform drug pricing to become a life sciences superpower
Shares jump on higher profits as Emma Walmsley is ‘hopeful’ standoff with NHS can be resolved GSK’s outgoing chief executive, Emma Walmsley, has said Britain will struggle to be a “life sciences super...
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
GSK Stock Rises as Strong Performance Boosts Outlook
GSK Stock Rises as Strong Performance Boosts Outlook
GSK Shares Leap 4% as Pharma Giant Boosts Guidance on Vaccine Breakthrough
GlaxoSmithKline plc (GSK), the pharmaceutical giant of the FTSE 100, shocked investors today with the second boost in its Full-Year profit expectations for this quarter, fuelled by blockbuster vaccine...
GSK rises on higher profit growth projected for 2025
GSK jumps after Q3 earnings beat and boosted 2025 outlook. Read more here.